Drugs / FS222
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04740424 | Dec 2020 → Oct 2027 expected | cancer of unknown primary site, metastatic malignant neoplasm | invoX Pharma Limited | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FS222 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04740424 ↗ |
| Modality | Monoclonal antibody | “CD137/PD-L1 Bispecific Antibody” NCT04740424 ↗ |
| Route | Intravenous | “Dosing of participants will occur intravenously (IV)” NCT04740424 ↗ |